Long Term Follow Up For Gene and Cellular Therapies

David T Chonzi, MD
VP: Pharmacovigilance and Epidemiology
Allogene Therapeutics
Forum on Regenerative Medicine Nov 13 2019; Washington DC
Disclosures

• Full-time employee of Allogene Therapeutics
• Equity interest in Allogene Therapeutics
• Previously an employee of Kite Pharma (Head of PV and Risk Management)
Disclaimer

This slide is not intended for product promotion. All information is related to investigational therapies not available for commercial use. The safety and efficacy of the therapies have not been established for FDA approval.

Forward-Looking Statements

To the extent statements contained in this Presentation are not descriptions of historical facts regarding Allogene Therapeutics, Inc. ("Allogene," “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance, or achievements to be materially different from those anticipated by such statements. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this Presentation include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and initiating clinical trials, and (ii) our plans to research, discover and develop additional product candidates. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-Q for the quarter ended September 30, 2019 filed with the SEC on November 5, 2019.

Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Aim of LTFU

• Identify and mitigate the long term risks to the patients receiving the GT product
• Understand the persistence of the product
Is a LTFU Study Required?

• Will depend on
  – Product characteristics e.g. Propensity of GT products/vectors to modify the host genome
  – Patient related factors, life expectancy, co-morbidities
  – Pre-clinical data e.g. persistence of the GT product
  – Clinical data: What has previously been observed?

• Key questions
  – Does your GT product utilize genome editing technology
  – Are vector sequences integrated or is the human genome otherwise genetically altered
  – Does the GT product have the potential for latency and reactivation
  – Do preclinical study results show persistence of the GT product
A dedicated Protocol required for LTFU

- Establish a dedicated LTFU protocol detailing patient schedules, sampling plan, methods of monitoring, and the clinical events of interest that will be monitored.

- Patients should be consented. Informed consent document should describe purposes of research, the expected duration of the subjects participation, procedures, duration, visits. If any blood or tissue will be stored, the informed consent should state so.

- Duration of the LTFU should be sufficient to observe the subjects for risk of interest.

- Protocol should describe how the data will be recorded.

- Protocol should describe steps that would be taken to assess causality for events of interest.
Lots of Guidance on LTFU

Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up

Draft Guidance for Industry

This guidance document is for comment purposes only.

Guidance for Industry

Gene Therapy Clinical Trials – Observing Subjects for Delayed Adverse Events

Long Term Follow-Up After Administration of Human Gene Therapy Products

Draft Guidance for Industry

1. 26 January 2019
2. EMEA/149995/2008 rev.1
3. Committee for Medicinal Products for Human Use (CHMP)
4. 
5. Guideline on safety and efficacy follow-up and risk management of Advanced Therapy Medicinal Products
6. Draft

European Medicines Agency

London, 22 October 2009

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

GUIDELINE ON FOLLOW-UP OF PATIENTS ADMINISTERED WITH GENE THERAPY MEDICINAL PRODUCTS

For Investigational Purposes Only
# Guidance for RCR is Evolving Due to Increased Experience

<table>
<thead>
<tr>
<th></th>
<th>FDA 2006 Guidance</th>
<th>FDA 2018 draft guidance</th>
<th>EU 2009 guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pre-treatment</strong></td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>RCR testing in 1st Year</strong></td>
<td>3, 6, 12</td>
<td>3, 6, 12</td>
<td>3, 6, 12</td>
</tr>
<tr>
<td><strong>RCR testing: Subsequent years</strong></td>
<td>RCR Sample collection Yearly thereafter. Samples archived</td>
<td>No sample collection if no positive tests in the first year</td>
<td>3, 6 and 12 for 5 years then yearly. Samples archived for 5 years if negative results during the first year of treatment</td>
</tr>
<tr>
<td><strong>Clinical FU</strong></td>
<td>Physical examination at the time of the annual sample collection</td>
<td>Yearly visits for the first 5 years by attendance at Healthcare Facility. (Hx and Physical examination) Then subsequently the yearly check up can be by phone or questionnaire</td>
<td>Physical attendance at clinic</td>
</tr>
<tr>
<td><strong>Events of interest</strong></td>
<td>Malignancy, neuro events, Hematologic disorders</td>
<td>Same as in 2006</td>
<td>Same as in the FDA Guidance</td>
</tr>
</tbody>
</table>
Monitoring: Chimeric Antigen Receptor (CAR)-T Cell LTFU

- CAR T products are using non-replicating Gammaretroviruses or Lentiviruses to deliver CAR-encoding sequences into T cells
- These viruses can integrate or have the potential for latency followed by reactivation
- Autologous CAR T products are already in late stage development or being marketed (YESCARTA and KYMRIAH)
- Recently allogeneic CAR T products using genome editing are entering clinical studies.
- Currently there is a mandatory 15 year follow for CAR T products
- Long term monitoring for RCR is clear and specific with regards to the type of testing and the schedules
- Guidance for monitoring of insertional mutagenesis not as clear
Post-Licensure Monitoring for CAR T Therapy

• Testing for RCR and vector integration should continue after FDA licensure.

• Using data from clinical studies to decide the extent of post-marketing testing for RCR.
  – RCR and vector persistency monitoring can be event driven: Only test in patients who develop an AE suggestive of a retrovirus-associated disease e.g. Primary secondary malignancy, neurotoxicity, persistent hematological disorder
  – Centre for International Blood and Marrow Transplant Research (CIBMTR) and European Society for Blood and Marrow Transplantation (EBMT) are running post licensure LTFU for CAR-T therapies
Suggested recommendations

• Provide more clarity on monitoring for off target effects of genome editing and insertional mutagenesis.

• Combine Is there a way of combining LTFU data from studies with the data combined from post marketing experience?

• Stakeholders should widely share the experiences and learnings from LTFU studies.
As more Gene Therapy products enter the clinic, it is important to harmonize conduct of LTFU studies as that will lead to better understanding of the magnitude of the risks.